Regulation of motor proteins, axonal transport deficits and adult-onset neurodegenerative diseases

Neurobiology of Disease

Volumn 105, Issue , 2017, Pages 273-282

  Brady, Scott T ^a   Morfini, Gerardo A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Axonal transport; Dynen; Huntington's disease; Kinases; Kinesin; Neurodegeneration; Parkinson's disease; Signaling

Indexed keywords

AMYLOID PRECURSOR PROTEIN; KINESIN 1; MICROTUBULE PROTEIN; MOLECULAR MOTOR; PROTEIN KINASE; TAU PROTEIN; MICROTUBULE ASSOCIATED PROTEIN;

ALZHEIMER DISEASE; BRAIN REGION; CELL DEATH; CELLS BY BODY ANATOMY; CEREBELLUM; CONTROLLED STUDY; CORTICOBASAL DEGENERATION; DEGENERATIVE DISEASE; FRONTAL CORTEX; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; HIPPOCAMPUS; HUMAN; HUNTINGTON CHOREA; MOTOR CORTEX; MOTOR NEURON DISEASE; NERVE CELL NECROSIS; NERVE FIBER TRANSPORT; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; RISK FACTOR; ANIMAL; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; AXONAL TRANSPORT; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; MOLECULAR MOTOR PROTEINS; NEURODEGENERATIVE DISEASES; SIGNAL TRANSDUCTION;

EID: 85017456841     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2017.04.010     Document Type: Review

References (178)

1. Ackerley, S., et al. p38alpha stress-activated protein kinase phosphorylates neurofilaments and is associated with neurofilament pathology in amyotrophic lateral sclerosis. Mol. Cell. Neurosci. 26 (2004), 354–364.
2. Adalbert, R., Coleman, M.P., Review: axon pathology in age-related neurodegenerative disorders. Neuropathol. Appl. Neurobiol. 39 (2013), 90–108.
3. Arendt, T., Synaptic degeneration in Alzheimer's disease. Acta Neuropathol. 118 (2009), 167–179.
4. Bateup, H.S., et al. Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat. Neurosci. 11 (2008), 932–939.
5. Bellucci, A., et al. Review: Parkinson's disease: from synaptic loss to connectome dysfunction. Neuropathol. Appl. Neurobiol. 42 (2016), 77–94.
6. Bendotti, C., et al. Activated p38MAPK is a novel component of the intracellular inclusions found in human amyotrophic lateral sclerosis and mutant SOD1 transgenic mice. J. Neuropathol. Exp. Neurol. 63 (2004), 113–119.
7. Bendotti, C., et al. Inter- and intracellular signaling in amyotrophic lateral sclerosis: role of p38 mitogen-activated protein kinase. Neurodegener. Dis. 2 (2005), 128–134.
8. Bertran-Gonzalez, J., et al. Opposing patterns of signaling activation in dopamine D1 and D2 receptor-expressing striatal neurons in response to cocaine and haloperidol. J. Neurosci. 28 (2008), 5671–5685.
9. Black, M.M., Axonal transport: the orderly motion of axonal structures. Methods Cell Biol. 131 (2016), 1–19.
10. Blair, M.A., et al. Mutation in KIF5A can also cause adult-onset hereditary spastic paraplegia. Neurogenetics 7 (2006), 47–50.
11. Borchelt, D.R., et al. Axonal transport of mutant superoxide dismutase 1 and focal axonal abnormalities in the proximal axons of transgenic mice. Neurobiol. Dis. 5 (1998), 27–35.
12. Bosco, D.A., et al. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat. Neurosci. 13 (2010), 1396–1403.
13. Boulanger, L.M., et al. Cellular and molecular characterization of a brain-enriched protein tyrosine phosphatase. J. Neurosci. 15 (1995), 1532–1544.
14. Brady, S.T., A kinesin medley: biochemical and functional heterogeneity. Trends Cell Biol. 5 (1995), 159–164.
15. Brady, S., Morfini, G., A perspective on neuronal cell death signaling and neurodegeneration. Mol. Neurobiol. 42 (2010), 25–31.
16. Brady, S.T., Sperry, A.O., Biochemical and functional diversity of microtubule motors in the nervous system. Curr. Op. Neurobiol. 5 (1995), 551–558.
17. Brady, S.T., et al. Fast axonal transport in extruded axoplasm from squid giant axon. Science 218 (1982), 1129–1131.
18. Brady, S.T., Cytotypic specializations of the neuronal cytoskeleton and cytomatrix: Implications for neuronal growth and regeneration. Haber, B. Cellular and Molecular Aspects of Neural Development and Regeneration, 1988, Springer-Verlag, New York City, 311–322.
19. Brady, S.T., et al. Fast axonal transport in isolated Axoplasm. Cell Motil. Cytoskeleton, 17, 1990, 22 (video supplement 2).
20. Braunstein, K.E., et al. A point mutation in the dynein heavy chain gene leads to striatal atrophy and compromises neurite outgrowth of striatal neurons. Hum. Mol. Genet. 19 (2010), 4385–4398.
21. Breuer, A.C., Atkinson, M.B., Fast axonal transport alterations in amyotrophic lateral sclerosis (ALS) and in parathyroid hormone (PTH)-treated axons. Cell Motil. Cytoskeleton 10 (1988), 321–330.
22. Brill, L.B. 2nd, Pfister, K.K., Biochemical and molecular analysis of the mammalian cytoplasmic dynein intermediate chain. Methods 22 (2000), 307–316.
23. Britt, D.J., et al. Mechanisms of polarized organelle distribution in neurons. Front. Cell. Neurosci., 10, 2016, 88.
24. Carboni, L., et al. Differential expression of SAPK isoforms in the rat brain. An in situ hybridisation study in the adult rat brain and during post-natal development. Brain Res. Mol. Brain Res. 60 (1998), 57–68.
25. Chahine, M., O'Leary, M.E., Regulation/modulation of sensory neuron sodium channels. Handb. Exp. Pharmacol. 221 (2014), 111–135.
26. Cheng, H.C., et al. Clinical progression in Parkinson disease and the neurobiology of axons. Ann. Neurol. 67 (2010), 715–725.
27. Coffey, E.T., Nuclear and cytosolic JNK signalling in neurons. Nat. Rev. Neurosci. 15 (2014), 285–299.
28. Coleman, M., Molecular signaling how do axons die?. Adv. Genet. 73 (2011), 185–217.
29. Collard, J.-F., et al. Defective axonal transport in a transgenic mouse model of amyotrophic lateral sclerosis. Nature 375 (1995), 61–64.
30. Conforti, L., et al. Neuronal death: where does the end begin?. Trends Neurosci. 30 (2007), 159–166.
31. Cox, K., et al. Analysis of isoform-specific tau aggregates suggests a common toxic mechanism involving similar pathological conformations and axonal transport inhibition. Neurobiol. Aging 47 (2016), 113–126.
32. Crews, L., Masliah, E., Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum. Mol. Genet. 19 (2010), R12–R20.
33. Crimella, C., et al. Mutations in the motor and stalk domains of KIF5A in spastic paraplegia type 10 and in axonal Charcot-Marie-Tooth type 2. Clin. Genet. 8 (2011), 157–164.
34. Cyr, J.L., et al. Molecular genetics of kinesin light chains: generation of isoforms by alternative splicing. Proc. Natl. Acad. Sci. U. S. A. 88 (1991), 10114–10118.
35. Dahlström, A., et al. The axonal transport motor kinesin is bound to anterogradely transported organelles: quantitative cytofluorimetric studies of fast axonal transport in the rat. Acta Physiol. Scand. 141 (1991), 469–476.
36. de Vos, K.J., et al. Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. Hum. Mol. Genet. 16 (2007), 2720–2728.
37. DeBerg, H.A., et al. Motor domain phosphorylation modulates kinesin-1 transport. J. Biol. Chem. 288 (2013), 32612–32621.
38. Deboer, S.R., et al. Conventional kinesin holoenzymes are composed of heavy and light chain homodimers. Biochemistry 47 (2008), 4535–4543.
39. Delcroix, J.D., et al. Trafficking the NGF signal: implications for normal and degenerating neurons. Prog. Brain Res. 146 (2004), 3–23.
40. Djaldetti, R., et al. Neuroprotection in progressive brain disorders. Isr. Med. Assoc. J. 5 (2003), 576–580.
41. Donelan, M.J., et al. Ca2 +− dependent dephosphorylation of kinesin heavy chain on beta-granules in pancreatic beta-cells. Implications for regulated beta-granule transport and insulin exocytosis. J. Biol. Chem. 277 (2002), 24232–24242.
42. Elluru, R., et al. Fast axonal transport of kinesin in the rat visual system: functionality of the kinesin heavy chain isoforms. Mol. Biol. Cell 6 (1995), 21–40.
43. Eschbach, J., Dupuis, L., Cytoplasmic dynein in neurodegeneration. Pharmacol. Ther. 130 (2011), 348–363.
44. Falnikar, A., Baas, P.W., Critical roles for microtubules in axonal development and disease. Results Probl. Cell Differ. 48 (2009), 47–64.
45. Fan, Y., et al. Protein kinase C delta mediated cytotoxicity of 6-Hydroxydopamine via sustained extracellular signal-regulated kinase 1/2 activation in PC12 cells. Neurol. Res. 36 (2014), 53–64.
46. Farrer, M.J., et al. DCTN1 mutations in Perry syndrome. Nat. Genet. 41 (2009), 163–165.
47. Feiguin, F., et al. Kinesin-mediated organelle translocation revealed by specific cellular manipulations. J. Cell Biol. 127 (1994), 1021–1039.
48. Fink, J.K., Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms. Acta Neuropathol. 126 (2013), 307–328.
49. Fischer, L.R., Glass, J.D., Axonal degeneration in motor neuron disease. Neurodegener. Dis. 4 (2007), 431–442.
50. Fischer, L.R., et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp. Neurol. 185 (2004), 232–240.
51. Gao, B., Roux, P.P., Translational control by oncogenic signaling pathways. Biochim. Biophys. Acta 1849 (2015), 753–765.
52. Gatto, R.G., et al. Analysis of YFP(J16)-R6/2 reporter mice and postmortem brains reveals early pathology and increased vulnerability of callosal axons in Huntington's disease. Hum. Mol. Genet. 2 (2015), 5285–5298.
53. Gerdts, J., et al. Axon self-destruction: new links among SARM1, MAPKs, and NAD + metabolism. Neuron 89 (2016), 449–460.
54. Gibbs, K.L., et al. Regulation of axonal transport by protein kinases. Trends Biochem. Sci. 40 (2015), 597–610.
55. Gindhart, J.G. Jr., Goldstein, L.S., Tetratrico peptide repeats are present in the kinesin light chain. Trends Biochem. Sci. 21 (1996), 52–53.
56. Gonzalez de Aguilar, J.L., et al. A mouse model of familial amyotrophic lateral sclerosis expressing a mutant superoxide dismutase 1 shows evidence of disordered transport in the vasopressin hypothalamo-neurohypophysial axis. Eur. J. Neurosci. 11 (1999), 4179–4187.
57. Gonzalez-Dominguez, R., et al. Region-specific metabolic alterations in the brain of the APP/PS1 transgenic mice of Alzheimer's disease. Biochim. Biophys. Acta 1842 (2014), 2395–2402.
58. Gordon, R., et al. Proteolytic activation of proapoptotic kinase protein kinase Cδ by tumor necrosis factor alpha death receptor signaling in dopaminergic neurons during neuroinflammation. J. Neuroinflammation, 9, 2012, 82.
59. Gordon, R., et al. Protein kinase Cδ upregulation in microglia drives neuroinflammatory responses and dopaminergic neurodegeneration in experimental models of Parkinson's disease. Neurobiol. Dis. 93 (2016), 96–114.
60. Gould, T.W., et al. Complete dissociation of motor neuron death from motor dysfunction by Bax deletion in a mouse model of ALS. J. Neurosci. 26 (2006), 8774–8786.
61. Grabinski, T., Kanaan, N.M., Novel non-phosphorylated serine 9/21 GSK3β/α antibodies: expanding the tools for studying GSK3 regulation. Front. Mol. Neurosci., 9, 2016, 123.
62. Grant, P., Pant, H.C., Neurofilament protein synthesis and phosphorylation. J. Neurocytol. 29 (2000), 843–872.
63. Grant, P., et al. Squid (Loligo pealei) giant fiber system: a model for studying neurodegeneration and dementia?. Biol. Bull. 210 (2006), 318–333.
64. Gratuze, M., et al. Tau hyperphosphorylation and deregulation of calcineurin in mouse models of Huntington's disease. Hum. Mol. Genet. 24 (2015), 86–99.
65. Gratuze, M., et al. Is Huntington's disease a tauopathy?. Brain 139 (2016), 1014–1025.
66. Ha, J., et al. A neuron-specific cytoplasmic dynein isoform preferentially transports TrkB signaling endosomes. J. Cell Biol. 181 (2008), 1027–1039.
67. Hafezparast, M., et al. Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science 300 (2003), 808–812.
68. Han, I., et al. Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features. J. Neurochem. 113 (2010), 1073–1091.
69. Hanrott, K., et al. Differential activation of PKC delta in the substantia nigra of rats following striatal or nigral 6-hydroxydopamine lesions. Eur. J. Neurosci. 27 (2008), 1086–1096.
70. Harrington, A.W., Ginty, D.D., Long-distance retrograde neurotrophic factor signalling in neurons. Nat. Rev. Neurosci. 14 (2013), 177–187.
71. He, Y., et al. Role of cytoplasmic dynein in the axonal transport of microtubules and neurofilaments. J. Cell Biol. 168 (2005), 697–703.
72. Henstridge, C.M., et al. Synaptic pathology: a shared mechanism in neurological disease. Ageing Res. Rev. 28 (2016), 72–84.
73. Hernandez, F., Avila, J., The role of glycogen synthase kinase 3 in the early stages of Alzheimers' disease. FEBS Lett. 582 (2008), 3848–3854.
74. Hernandez, F., et al. GSK3: a possible link between beta amyloid peptide and tau protein. Exp. Neurol. 223 (2010), 322–325.
75. Hirokawa, N., et al. Molecular motors in neurons: transport mechanisms and roles in brain function, development, and disease. Neuron 68 (2010), 610–638.
76. Hollenbeck, P.J., Kinesin heavy and light chains are phosphorylated in vivo in neurons. J. Cell Biol., 115, 1990, 390a (abstract).
77. Hollenbeck, P.J., Phosphorylation of neuronal kinesin heavy and light chains in vivo. J. Neurochem. 60 (1993), 2265–2275.
78. Holmgren, A., et al. Neurofilament phosphorylation and their proline-directed kinases in health and disease. J. Peripher. Nerv. Syst. 17 (2012), 365–376.
79. Hoogenraad, C.C., Akhmanova, A., Bicaudal D family of motor adaptors: linking dynein motility to cargo binding. Trends Cell Biol. 26 (2016), 327–340.
80. Hu, J.H., Krieger, C., Protein phosphorylation networks in motor neuron death. Prog. Drug Res. 59 (2002), 71–109.
81. Hu, J.H., et al. Protein kinase and protein phosphatase expression in the central nervous system of G93A mSOD over-expressing mice. J. Neurochem. 85 (2003), 422–431.
82. Ikeda, K., et al. CK1 activates minus-end-directed transport of membrane organelles along microtubules. Mol. Biol. Cell 22 (2011), 1321–1329.
83. Ito, K., Enomoto, H., Retrograde transport of neurotrophic factor signaling: implications in neuronal development and pathogenesis. J. Biochem. 160 (2016), 77–85.
84. Jagmag, S.A., et al. Evaluation of models of Parkinson's disease. Front. Neurosci., 9, 2015, 503.
85. Jeppesen, G.M., Hoerber, J.K., The mechanical properties of kinesin-1: a holistic approach. Biochem. Soc. Trans. 40 (2012), 438–443.
86. Julien, J.P., Mushynski, W.E., Neurofilaments in health and disease. Prog. Nucl. Acid Res. Molec. Biol. 61 (1998), 1–23.
87. Kanaan, N.M., et al. Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases. J. Neurosci. 31 (2011), 9858–9868.
88. Kanaan, N.M., et al. Axonal degeneration in Alzheimer's disease: when signaling abnormalities meet the axonal transport system. Exp. Neurol. 246 (2013), 44–53.
89. Kanai, Y., et al. KIF5C, a novel neuronal kinesin enriched in motor neurons. J. Neurosci. 20 (2000), 6374–6384.
90. Kang, M., et al. Biochemical analysis of axon-specific phosphorylation events using isolated squid axoplasms. Methods Cell Biol. 131 (2016), 199–216.
91. Karki, S., et al. Casein kinase II binds to and phosphorylates cytoplasmic dynein. J. Biol. Chem. 272 (1997), 5887–5891.
92. Kaul, S., et al. Caspase-3 dependent proteolytic activation of protein kinase C delta mediates and regulates 1-methyl-4-phenylpyridinium (MPP +)-induced apoptotic cell death in dopaminergic cells: relevance to oxidative stress in dopaminergic degeneration. Eur. J. Neurosci. 18 (2003), 1387–1401.
93. Kawakami, F., Ichikawa, T., The role of alpha-Synuclein and LRRK2 in tau phosphorylation. Parkinsons Dis. 2015, 2015, 734746.
94. Khan, S.S., Bloom, G.S., Tau: the center of a signaling nexus in Alzheimer's disease. Front. Neurosci., 10, 2016, 31.
95. Krieger, C., et al. Aberrant protein kinases and phosphoproteins in amyotrophic lateral sclerosis. Trends Pharmacol. Sci. 24 (2003), 535–541.
96. Lapointe, N.E., et al. The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity. J. Neurosci. Res. 87 (2009), 440–451.
97. Lawrence, C.J., et al. A standardized kinesin nomenclature. J. Cell Biol. 167 (2004), 19–22.
98. Lazarov, O., et al. Impairments in fast axonal transport and motor neuron deficits in transgenic mice expressing familial Alzheimer's disease-linked mutant presenilin 1. J. Neurosci. 27 (2007), 7011–7020.
99. Leopold, P.L., et al. Association of kinesin with characterized membrane-bounded organelles. Cell Motil. Cytoskeleton 23 (1992), 19–33.
100. Leopold, P.L., et al. The nervous system of Loligo pealei provides multiple models for analysis of organelle motility. Abbott, N.J., et al. (eds.) Cephalopod Neurobiology: Neuroscience Studies in Squid, Octopus and Cuttlefish, 1994, Oxford Univ. Press, Oxford, 15–34.
101. Li, J.Y., Conforti, L., Axonopathy in Huntington's disease. Exp. Neurol. 246 (2013), 62–71.
102. Lingor, P., et al. Axonal degeneration as a therapeutic target in the CNS. Cell Tissue Res. 349 (2012), 289–311.
103. Llinas, R., et al. Microdomains of high calcium concentration in a presynaptic terminal. Science 256 (1992), 677–679.
104. Luo, L., O'Leary, D.D., Axon retraction and degeneration in development and disease. Annu. Rev. Neurosci. 28 (2005), 127–156.
105. Maeder, C.I., et al. Axon and dendritic trafficking. Curr. Opin. Neurobiol. 27 (2014), 165–170.
106. Marinkovic, P., et al. Axonal transport deficits and degeneration can evolve independently in mouse models of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 4296–4301.
107. Martin, L.J., Neuronal cell death in nervous system development, disease, and injury (Review). Int. J. Mol. Med. 7 (2001), 455–478.
108. Mattson, M.P., Magnus, T., Ageing and neuronal vulnerability. Nat. Rev. Neurosci. 7 (2006), 278–294.
109. McGoldrick, P., et al. Rodent models of amyotrophic lateral sclerosis. Biochim. Biophys. Acta 1832 (2013), 1421–1436.
110. Moreno, H.H., et al. Synaptic transmission block by presynaptic injection of oligomeric amyloid beta. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 5901–5906.
111. Moreno, H., et al. Tau pathology mediated presynaptic dysfunction. Neuroscience 325 (2016), 30–38.
112. Morfini, G., et al. Regulation of kinesin: implications for neuronal development. Dev. Neurosci. 23 (2001), 364–376.
113. Morfini, G., et al. Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. EMBO J. 23 (2002), 281–293.
114. Morfini, G., et al. A novel CDK5-dependent pathway for regulating GSK3 activity and kinesin-driven motility in neurons. EMBO J. 23 (2004), 2235–2245.
115. Morfini, G., et al. 1-methyl-4-phenylpyridinium affects fast axonal transport by activation of caspase and protein kinase C. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 2442–2447.
116. Morfini, G.A., et al. Axonal transport defects in neurodegenerative diseases. J. Neurosci. 29 (2009), 12776–12786.
117. Morfini, G.A., et al. Pathogenic huntingtin inhibits fast axonal transport by activating JNK3 and phosphorylating kinesin. Nat. Neurosci. 12 (2009), 864–871.
118. Morfini, G., et al. Axonal transport. Brady, S.T., et al. (eds.) Basic Neurochemistry: Principles of Molecular, Cellular and Medical Neurobiology, 2012, Elsevier, Boston, 146–164.
119. Morfini, G.A., et al. Inhibition of fast axonal transport by pathogenic SOD1 involves activation of p38 MAP kinase. PLoS One, 8, 2013, e65235.
120. Morfini, G., et al. Conventional kinesin: biochemical heterogeneity and functional implications in health and disease. Brain Res. Bull. 126 (2016), 347–353.
121. Morotz, G.M., et al. Amyotrophic lateral sclerosis-associated mutant VAPBP56S perturbs calcium homeostasis to disrupt axonal transport of mitochondria. Hum. Mol. Genet. 21 (2012), 1979–1988.
122. Nakajima, K., et al. Molecular motor KIF5A is essential for GABA(A) receptor transport, and KIF5A deletion causes epilepsy. Neuron 76 (2012), 945–961.
123. Oblinger, M.M., et al. Cytotypic differences in the protein composition of the axonally transported cytoskeleton in mammalian neurons. J. Neurosci. 7 (1987), 453–462.
124. Ozdinler, P.H., et al. Corticospinal motor neurons and related subcerebral projection neurons undergo early and specific neurodegeneration in hSOD1G(3)A transgenic ALS mice. J. Neurosci. 31 (2011), 4166–4177.
125. Pardo, C.A., et al. Superoxide dismutase is an abundant component in cell bodies, dendrites, and axons of motor neurons and in a subset of other neurons. Proc. Natl. Acad. Sci. U. S. A. 92 (1995), 954–958.
126. Parent, M., Parent, A., Relationship between axonal collateralization and neuronal degeneration in basal ganglia. J. Neural Transm. Suppl., 2006, 85–88.
127. Perez-Navarro, E., et al. Cellular and molecular mechanisms involved in the selective vulnerability of striatal projection neurons in Huntington's disease. Histol. Histopathol. 21 (2006), 1217–1232.
128. Pfister, K.K., Distinct functional roles of cytoplasmic dynein defined by the intermediate chain isoforms. Exp. Cell Res. 334 (2015), 54–60.
129. Pigino, G., et al. Alzheimer's presenilin 1 mutations impair kinesin-based axonal transport. J. Neurosci. 23 (2003), 4499–4508.
130. Pigino, G., et al. Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 5907–5912.
131. Pigino, G., et al. Intracellular trafficking. Brady, S.T., et al. (eds.) Basic Neurochemistry: Principles of Molecular, Cellular and Medical Neurobiology, 2012, Elsevier, Boston, 119–145.
132. Poudel, G.R., et al. White matter connectivity reflects clinical and cognitive status in Huntington's disease. Neurobiol. Dis. 65 (2014), 180–187.
133. Pouladi, M.A., et al. Choosing an animal model for the study of Huntington's disease. Nat. Rev. Neurosci. 14 (2013), 708–721.
134. Prensa, L., et al. The nigrostriatal pathway: axonal collateralization and compartmental specificity. J. Neural Transm. Suppl., 2009, 49–58.
135. Puls, I., et al. Mutant dynactin in motor neuron disease. Nat. Genet. 33 (2003), 455–456.
136. Puls, I., et al. Distal spinal and bulbar muscular atrophy caused by dynactin mutation. Ann. Neurol. 57 (2005), 687–694.
137. Rahman, A., et al. Two kinesin light chain genes in mice. J. Biol. Chem. 273 (1998), 15395–15403.
138. Ratner, N., et al. A role for Cdk5 kinase in fast anterograde axonal transport: novel effects of olomoucine and the APC tumor suppressor protein. J. Neurosci. 18 (1998), 7717–7726.
139. Reaume, A.G., et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat. Genet. 13 (1996), 43–47.
140. Reid, E., et al. A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10). Am. J. Hum. Genet. 71 (2002), 1189–1194.
141. Ribeiro, F.M., et al. Animal models of neurodegenerative diseases. Rev. Bras. Psiquiatr. 35:Suppl. 2 (2013), S82–S91.
142. Rosas, H.D., et al. Altered white matter microstructure in the corpus callosum in Huntington's disease: implications for cortical “disconnection”. NeuroImage 49 (2010), 2995–3004.
143. Rosenberg, R.N., et al. Genomics of Alzheimer disease: a review. JAMA Neurol. 73 (2016), 867–874.
144. Roy, S., et al. Axonal transport defects: a common theme in neurodegenerative diseases. Acta Neuropathol. (Berl). 109 (2005), 5–13.
145. Rudrabhatla, P., Regulation of neuronal cytoskeletal protein phosphorylation in neurodegenerative diseases. J. Alzheimers Dis. 41 (2014), 671–684.
146. Sasaki, S., Iwata, M., Impairment of fast axonal transport in the proximal axons of anterior horn neurons in amyotrophic lateral sclerosis. Neurology 47 (1996), 535–540.
147. Sasaki, S., et al. Impairment of axonal transport in the axon hillock and the initial segment of anterior horn neurons in transgenic mice with a G93A mutant SOD1 gene. Acta Neuropathol. (Berl). 110 (2005), 48–56.
148. Serulle, Y., et al. 1-methyl-4-phenylpyridinium induces synaptic dysfunction through a pathway involving caspase and PKC{delta} enzymatic activities. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 2437–2441.
149. Solowska, J., et al. Quantitative and functional analyses of spastin in the nervous system: implications for hereditary spastic paraplegia. J. Neurosci. 28 (2008), 2147–2157.
150. Song, Y., et al. Fast axonal transport in isolated axoplasm from the squid giant axon. Methods Cell Biol. 131 (2016), 331–348.
151. Spillantini, M.G., Goedert, M., Tau pathology and neurodegeneration. Lancet Neurol. 12 (2013), 609–622.
152. Stoothoff, W.H., Johnson, G.V., Tau phosphorylation: physiological and pathological consequences. Biochim. Biophys. Acta 1739 (2005), 280–297.
153. Strong, M.J., et al. Tau protein hyperphosphorylation in sporadic ALS with cognitive impairment. Neurology 66 (2006), 1770–1771.
154. Susalka, S.J., Pfister, K.K., Cytoplasmic dynein subunit heterogeneity: implications for axonal transport. J. Neurocytol. 29 (2000), 819–829.
155. Szodorai, A., et al. APP anterograde transport requires Rab3A GTPase activity for assembly of the transport vesicle. J. Neurosci. 29 (2009), 14534–14544.
156. Tanaka, Y., et al. Targeted disruption of mouse conventional kinesin heavy chain, kif5B, results in abnormal perinuclear clustering of mitochondria. Cell 93 (1998), 1147–1158.
157. Tenreiro, S., et al. Protein phosphorylation in neurodegeneration: friend or foe?. Front. Mol. Neurosci., 7, 2014, 42.
158. Tessa, A., et al. A novel KIF5A/SPG10 mutation in spastic paraplegia associated with axonal neuropathy. J. Neurol. 255 (2008), 1090–1092.
159. Thapar, R., Denmon, A.P., Signaling pathways that control mRNA turnover. Cell. Signal. 25 (2013), 1699–1710.
160. Tsai, M.-Y., et al. Release of kinesin from vesicles by hsc70 and regulation of fast axonal transport. Mol. Biol. Cell 11 (2000), 2161–2173.
161. Vallee, R.B., et al. Dynein: an ancient motor protein involved in multiple modes of transport. J. Neurobiol. 58 (2004), 189–200.
162. van den Berg, R., Hoogenraad, C.C., Molecular motors in cargo trafficking and synapse assembly. Adv. Exp. Med. Biol. 970 (2012), 173–196.
163. Veeranna, et al. Neurofilament tail phosphorylation: identity of the RT-97 phosphoepitope and regulation in neurons by cross-talk among proline-directed kinases. J. Neurochem. 107 (2008), 35–49.
164. Vickers, J.C., et al. Axonopathy and cytoskeletal disruption in degenerative diseases of the central nervous system. Brain Res. Bull. 80 (2009), 217–223.
165. Wagey, R.T., Krieger, C., Abnormalities of protein kinases in neurodegenerative diseases. Prog. Drug Res. 51 (1998), 133–183.
166. Wagner, M.C., et al. Copurification of kinesin polypeptides with microtubule-stimulated mg-ATPase activity and kinetic analysis of enzymatic processes. Cell Motil. Cytoskeleton 12 (1989), 195–215.
167. Walaas, S.I., Greengard, P., Protein phosphorylation and neuronal function. Pharmacol. Rev. 43 (1991), 299–349.
168. Waldmeier, P., et al. Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases. Biochem. Pharmacol. 72 (2006), 1197–1206.
169. Wang, L., Brown, A., A hereditary spastic paraplegia mutation in kinesin-1A/KIF5A disrupts neurofilament transport. Mol. Neurodegener., 5, 2010, 52.
170. Wang, J.Z., et al. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur. J. Neurosci. 25 (2007), 59–68.
171. Whitmarsh, A.J., Regulation of gene transcription by mitogen-activated protein kinase signaling pathways. Biochim. Biophys. Acta 1773 (2007), 1285–1298.
172. Wishart, T.M., et al. Synaptic vulnerability in neurodegenerative disease. J. Neuropathol. Exp. Neurol. 65 (2006), 733–739.
173. Wong, P.C., et al. Familial amyotrophic lateral sclerosis and Alzheimer's disease. Transgenic models. Adv. Exp. Med. Biol. 446 (1998), 145–159.
174. Wong, P.C., et al. Genetically engineered mouse models of neurodegenerative diseases. Nat. Neurosci. 5 (2002), 633–639.
175. Xia, C.H., et al. Abnormal neurofilament transport caused by targeted disruption of neuronal kinesin heavy chain KIF5A. J. Cell Biol. 161 (2003), 55–66.
176. Xiao, S., et al. Neuronal intermediate filaments and ALS: a new look at an old question. Biochim. Biophys. Acta 1762 (2006), 1001–1012.
177. Zeitlin, S., et al. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat. Genet. 11 (1995), 155–163.
178. Zerr, I., Bahr, M., Is there a role of tau in Huntington's disease?. J. Neurochem. 139 (2016), 9–10.